-- Scott Roberts
WEDNESDAY, Nov. 21 (HealthDay News) -- Flucelvax is the first
seasonal flu vaccine to be approved by the U.S. Food and Drug
Administration using a manufacturing method called cell culture
technology, the agency said.
Other flu vaccines are produced inside eggs. But that process
takes longer than the newer method and could be harmful to people
with egg allergies, the FDA explained. In cell culture technology,
virus strains are grown inside mammalian animal cells.
This technology has been used for decades to produce other
vaccines, the agency said, and since it is quicker, it can be used
more efficiently to develop flu vaccines rapidly in the event of a
Flucelvax was evaluated in clinical studies in the United States
and Europe involving some 7,700 people ages 18 to 49. Common side
effects included pain, redness, injection-site soreness, headache
and fatigue -- reactions typically seen in people given egg-based
flu vaccines, the FDA said.
The U.S. Centers for Disease Control and Prevention recommends
the annual flu shot for anyone 6 months and older.
Flucelvax is produced by Novartis Vaccines and Diagnostics,
based in Marburg, Germany.
To learn more about flu vaccination, visit the U.S.
Department of Health
and Human Services.
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.